LANDSPITALI UNIVERSITY HOSPITAL

Their core work

Landspitali is Iceland's national university hospital and the country's primary academic medical center, serving as both a clinical care provider and a research institution. In H2020, they contributed clinical data, patient cohorts, and medical expertise to European health research — particularly in respiratory disease epidemiology, end-of-life care, and drug safety biomarkers. They also played a role in Europe's open science infrastructure through the OpenAIRE initiative, helping ensure research outputs from clinical settings are openly accessible.

What they specialise in

How they've shifted over time

Early H2020 participation (2015-2018) combined open access infrastructure work with clinical epidemiology — respiratory disease cohorts and thyroid health. In the later period (2018-2023+), their focus shifted toward deeper open science engagement (EOSC, open scholarship) and more applied clinical research in palliative care and pharmaceutical safety biomarkers. The trend shows a move from population-level epidemiology toward patient-centered care quality and translational medicine.

Moving toward translational clinical research — drug safety biomarkers and care quality benchmarking — suggesting growing interest in applied health outcomes rather than purely observational studies.

How they like to work

Landspitali operates exclusively as a consortium participant, never as coordinator — consistent with the role of a smaller-country academic hospital contributing specialized clinical data and patient populations to large European studies. With 139 unique partners across 40 countries from just 6 projects, they join very large consortia (averaging ~23 partners per project). This makes them an accessible, experienced partner comfortable working within complex multi-country research networks.

Despite only 6 projects, Landspitali has built connections with 139 partners across 40 countries — a remarkably broad network reflecting their participation in large pan-European consortia. Their reach extends well beyond the Nordic region into all major EU research ecosystems.

What sets them apart

As Iceland's only university hospital, Landspitali offers something rare: access to an exceptionally well-documented, genetically distinct Nordic population with comprehensive health records — invaluable for cohort studies and biomarker research. Their dual expertise in clinical health research and open science infrastructure is unusual for a hospital, making them a partner that understands both the medical and data-sharing dimensions of European research. For consortium builders, they bring an Icelandic node that adds geographic diversity and access to Iceland's unique patient datasets.

Highlights from their portfolio

• iLIVE
  Largest single grant (EUR 219,750) and their most recent major health project, addressing the growing European priority of end-of-life care quality.
• TransBioLine
  Running until 2025, this translational biomarker project signals a strategic shift toward pharmaceutical safety — a high-value area for industry collaboration.
• OpenAIRE-Advance
  Shows sustained commitment to open science infrastructure across two project generations (OpenAIRE2020 → OpenAIRE-Advance), unusual for a clinical institution.